Skip to Content

Additional Content In This Section

PEGASUS

PEGASUS

Objective

Status

Enrollment complete

Condition
Myocardial Infarction

Description

A randomized, double –blind, placebo controlled, parallel group, multinational trial, to assess the prevention of thrombotic events with Ticagrelor compared to placebo on a background of Acetyl Salicylic Acid (ASA) therapy in patients with history of myocardial infarction 

Purpose   

The purpose of this study is to see if a new investigational drug called Ticagrelor given twice daily in addition to current Acetyl Salicylic Acid (ASA) therapy will decrease the frequency of cardiovascular events

Phase
III

Key Inclusion Criteria

  • Men and women 50 years of age or older.
  • Documented history of heart attack within 1 to 3 years ago and have at least 1 of the following risk factors:
  • Age ≥65 years
  • Diabetes requiring medication
  • Documented history of a second prior MI greater than 1 year ago
  • Angiographic evidence of multivessel coronary artery disease (CAD) and or Chronic, non-end stage renal dysfunction

Key Exclusion Criteria

  • Persons who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start
  • Persons who have planned coronary, cerebrovascular, or peripheral arterial revascularization (invasive surgery) at study start

ClinicalTrials.gov Identifier

NCT01225562

IRB Protocol Number
D5132C00001
Principal Investigator(s)
Rabeea Aboufakher, MD

Clinical Trial Categories

  • Cardiology
Sponsor(s)
Aztra Zeneca in collaboration with the TIMI Study Group
Contact
Dianne Vold, LPN CCRC at 701-780-1559
or dvold@altru.org